4D Molecular Therapeutics, Inc. Common Stock (FDMT) — 分析摘要
4D Molecular Therapeutics, Inc. Common Stock（FDMT）的市值为590.72百万美元，最近一年的营收同比增长了+230194.6%。净利润率为-164.4%。当前市盈率为-3.7倍。
核心要点
- 营收同比变化+230194.6%
- 净利润率-164.4%
- 市盈率-3.7倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比，FDMT的营收增长为+230194.6%，市盈率为-3.7倍。
4D Molecular Therapeutics, Inc. Common Stock (FDMT)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
营业利润率为 -203.5% — 严重经营亏损
净利率为 -182.3% — 亏损超过收入（可能含一次性费用）
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
196
总部
EMERYVILLE, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。